Comparison of the Performance of Three Commonly Used Electrocardiographic Indexes for the Diagnosis of Left Ventricular Hypertrophy in Black Hypertensive Patients with Reduced Kidney Function Managed at a Tertiary Healthcare Hospital: A Post-Hoc Analysis

F. B. Lepira1*, C. M. B. Mpembe2, F. I. N. Mbutiwi1,3, J. R. Makulo1, P. K. Kayembe4, F. M. Kajingulu1, E. V. Kintoki2, J. R. M’buyamba-Kabangu2

1Division of Nephrology, University Hospital of Kinshasa, Democratic Republic of the Congo
2Division of Cardiology, University of Kinshasa Hospital, Democratic Republic of the Congo
3Division of Epidemiology and Biostatistics, University of Kikwit, Democratic Republic of the Congo
4Division of Epidemiology and Biostatistics, Kinshasa School of Public Health, Democratic Republic of the Congo

Email: *lepslepira@yahoo.fr

Abstract

Background: Reduced kidney function in blacks is associated with an increased frequency of left ventricular hypertrophy. Given the unavailability of echocardiography in most developing countries, the diagnostic performance of current ECG indexes needs to be evaluated. Objective: To compare the diagnostic performance of 3 commonly used ECG indexes (Sokolow-Lyon, Cornell voltage and Cornell product) in black hypertensive patients. Methods: Electrocardiography and echocardiography estimated left ventricular mass of 155 consecutive hypertensive patients who participated from January 2012 to January 2013 to an echocardiographic cross-sectional study of left ventricular structure was analyzed to compare Cornell voltage and Cornell product indexes with Sokolow-Lyon voltage index as a reference. Reduced kidney function was defined as eGFR < 60 ml/min/1.73 m². ROC curves in relation to LVH diagnosis were used to estimate the sensitivities and specificities of each index. P < 0.05 defined the level of the statistical significance. Results: The sensitivity and specificity were 43% and 85%, 23% and 77% and 26% and 77% for Sokolow-Lyon, Cornell voltage and Cornell product indexes, respectively. However, Sokolow-Lyon index (AUC; 95% CI: 0.64; 0.50 - 0.78)

DOI: 10.4236/wjcd.2017.74011  April 27, 2017
showed better performance than Cornell voltage (0.42; 0.25 - 0.59) and Cornell product (0.43; 0.28 - 0.59). Sokolow-Lyon index cut-point ≥ 37 mm corresponded to the highest Youden index (39.4% of sensitivity and 92.3% of specificity). **Conclusion:** Although the overall performance of the 3 ECG indexes versus echocardiography was low, Sokolow-Lyon index performed better than the two other indexes in diagnosing LVH.

**Keywords**
Performance ECG Indexes, Reduced Kidney Function, Black Africans

---

**1. Introduction**

Hypertensive patients with reduced kidney function (RKF) are at the increased risk for cardiovascular disease [1] [2]. Thus, the knowledge and management of factors underlying this increased risk could be of great help in reducing CV risk in hypertensive patients especially those with RKF. Among identified factors, left ventricular hypertrophy (LVH) is thought to play a central role in the development and progression of CVD [3]. LVH has been reported to be associated with cardiac arrhythmias, ischemic heart disease, congestive heart failure, and sudden death [4]. Given the prognostic importance of LVH, accurate diagnosis and appropriate management of LVH have become a major component of the care of patients with hypertension [3]. However, there is little information on the diagnosis of LVH in black Africans [5].

LVH can be detected by chest X radiography, electrocardiography (ECG) and echocardiography, computerized tomography (CT) scan and magnetic resonance imaging (MRI) [5]. However, in daily clinical practice, ECG and echocardiography are the most widely used not only for reasons of availability, but mainly by the prognostic association that clearly predicts the increased CV risk when LVH is found [5]. Although echocardiography is the gold standard, the ECG is still the most widely used cost-effective tool and recommended for routine assessment of LVH [3] [6] [7]. Despite the low sensitivity of available ECG indexes ranging from 7% to 35% in mild hypertension and 10% to 50% in moderate to severe hypertension [8], ECG is still in use in many parts of the world including Sub-Saharan Africa where echocardiography is not often available [9]. The most commonly used ECG indexes for the diagnosis of LVH include Sokolow-Lyon voltage, Cornell voltage and Cornell product indexes [4] [7] [10]. Given the differences of sensitivity of these different indexes, it appears thus rational to assess and compare them with echocardiography to assess their suitability for routine use for the diagnosis of LVH in hypertensive patients especially those with RKF [4] [7].

In the Democratic Republic of the Congo, the prevalence of hypertension and chronic kidney disease is estimated to be of 30% and 12%, respectively [11] [12] [13] [14]; both conditions are associated with LVH [15] [16]. However, the ac-
accuracy of commonly used ECG indexes relative to echocardiography as the gold standard for the diagnosis of LVH has not yet been evaluated. Therefore, the aim of the present post-hoc analysis was to compare the diagnostic performance of 3 commonly used ECG indexes namely Sokolow-Lyon voltage, Cornell voltage and Cornell product indexes in hypertensive black patients with RKF seen at tertiary level hospital in Kinshasa, the capital City.

2. Patients and Methods

To compare 3 ECG indexes (Sokolow-Lyon voltage, Cornell voltage and Cornell product) with echocardiography to assess their suitability for routine use in the diagnosis of LVH, we performed a post-hoc analysis of data from 155 consecutive adult black patients with established hypertension enrolled in an echocardiographic-based cross-sectional study of the relationship between renal function status and LV structure and function carried out at the outpatient cardiology clinic of the University of Kinshasa Hospital from January 2012 to January 2013. The details of the original study have been already described elsewhere [15]. In brief, according to American Society of Echocardiography (ASE) recommendations, LV end-diastolic internal diameter (LVIDd), interventricular septum thickness (IVSTd) and that of posterior wall of the LV (LVPWTd) were obtained during diastole, and the LV mass (LVM), in grams, was calculated according to the following formula: LVM = 0.8 × [1.04 [(IVSTd + LVIDd + LVPWTd)3 − (LVIDd)3]] + 0.6 g [17] and indexed to body surface area (g/m²) in non-obese patients and height in obese ones (g/m²) [18]. Overweight and obesity were defined as body mass index (BMI) ≥ 25 Kg/m² and ≥ 30 Kg/m³, respectively [19]. MetS was defined according to harmonized definition [20], Hemoglobin levels < 12 g/dl for men and <11 g/dl for women defined anemia [21]. Echocardiographic diagnosis of LVH was made when LVM index (LVMI) was >125 g/m² in men and >110 g/m² in women or >51 g/m² in both sexes [22] [23]. From the relative wall thickness (RWT) calculated using the following formula: RWT = 2 × LVPWTd/LVIDd, two geometric patterns defined: concentric and eccentric patterns when RWT was ≥0.42 and <0.42, respectively [24]. For the purpose of the present post-hoc analysis, patient’s ECG records were analyzed and evaluated for the presence of LVH using 3 ECG indexes: Sokolow-Lyon (SV1 + RV5 or V6 > 35 mm), Cornell voltage (SV3 + RaVL > 20 mm in women or >28 mm in men) and Cornell product (SV3 + RaVL × QRS > 2440 mm) [25] [26] [27]. RKF was defined as eGFR < 60 ml/min/1.73 m² using modification of diet in renal disease equation [28].

Statistical Analysis

Continuous variables were expressed as mean ± standard deviation (SD) or median (range) as appropriate. Categorical variables were expressed as percentages. Comparison of means or medians was done by student t test or Mann Whitney test, respectively. The sensitivity, specificity, positive and negative predictive values of each of the 3 indexes were estimated. Sensitivity and specificity were
calculated using $2 \times 2$ tables classifying ECG against echocardiographic LVH as gold standard. The specificity was calculated as true negatives divided by the sum of true negatives and false positives. Similarly, the sensitivity as true positives is divided by the sum of true positives and false negatives. Positive predictive value (PPV) was calculated as true positives divided by the sum of true positives and false positives, and negative predictive value (NPV) as true negatives divided by the sum of true negatives and false negatives. Analysis of the performance of LVM indexers and of sensitivities and specificities of the 3 ECG indexes was made using ROC curves [29]. The areas under the 3 ROC curves and their 95% confidence intervals (CI) were reported. The comparison of curves was made using the Chi-square statistic test. The reported optimal cut-point corresponded to the highest Youden index (sensitivity + specificity − 1). P value < 0.05 defined the level of statistical significance. The Ethical and Research Committee of the University of Kinshasa School of Medicine approved the study. The data were analyzed using the Statistical Package STATA/IC version 14.1 (StataCorp, Texas, USA).

3. Results

General characteristics of the study population as a whole and according to renal function status are summarized in Table 1 and Table 2. RKF was observed in 74

Table 1. Clinical characteristics of the whole study population and according to kidney function status.

| Variables             | All group n = 155 | NKF n = 81 | RKF n = 74 | P   |
|-----------------------|-------------------|------------|------------|-----|
| Gender, % M           |                   |            |            |     |
| M                     | 49                | 51         | 47         | 0.681|
| F                     | 51                | 49         | 53         |     |
| Age, years            | 58 ± 12           | 58 ± 12    | 59 ± 12    | 0.732|
| DHT, years            | 7 (2 - 13)        | 6 (1 - 13) | 8 (4 - 12) | 0.040|
| Smoking, %            | 20                | 22         | 18         | 0.470|
| Physical activity, %  | 60                | 66         | 54         | <0.001|
| BMI, Kg/m²            | 26 ± 5            | 25 ± 4     | 27 ± 5     | 0.047|
| Obesity, %            | 19                | 10         | 30         | 0.002|
| WC, cm                | 93 ± 14           | 90 ± 13    | 95 ± 14    | 0.031|
| Central obesity, %    | 47                | 39         | 55         | 0.048|
| SBP, mm Hg            | 158 ± 24          | 157 ± 24   | 159 ± 25   | 0.510|
| DBP, mm Hg            | 93 ± 17           | 94 ± 15    | 93 ± 18    | 0.890|
| PP, mm Hg             | 65 ± 20           | 63 ± 18    | 68 ± 22    | 0.180|
| HR, bpm               | 84 ± 14           | 83 ± 15    | 84 ± 14    | 0.600|
| AntiHT regimen, %     |                   |            |            | 0.530|
| - Monotherapy         | 84                | 64         | 63         |     |
| - Bitherapy           | 28                | 28         | 27         |     |
| - ≥3 drugs            | 3                 | 1          | 5          |     |
| Uncontrolled BP, %    | 69                | 62         | 77         | 0.040|

Data are expressed as mean ± standard deviation, median (interquartile range) or relative frequency in percent. Abbreviations: RKF & NKF, reduced and relatively normal kidney function M, male F, female DHT, duration of hypertension BMI, body mass index WC, waist circumference SBP, systolic blood pressure DBP, diastolic blood pressure PP, pulse pressure HR, heart rate AntiHT, antihypertensive BP, blood pressure.
Table 2. Biological characteristics of the whole study population and according to kidney function status.

| Variables                  | All group n = 155 | NKF n = 81 | RKF n = 74 | P     |
|----------------------------|-------------------|------------|------------|-------|
| Hb, g/dl                   | 12 ± 2            | 13 ± 2     | 11 ± 2     | <0.001|
| Ht, %                      | 37 ± 7            | 40 ± 5     | 35 ± 7     | <0.001|
| Anemia, %                  | 39                | 24         | 54         | <0.001|
| FPG, mg/dl                 | 92 (82 - 109)     | 90 (79 - 97) | 101 (86 - 128) | <0.001|
| Diabetes, %                | 21                | 6          | 38         | <0.001|
| Uric acid, mg/dl           | 6.4 ± 2.6         | 5.5 ± 2.2  | 7.4 ± 2.8  | <0.001|
| Hyperuricemia, %           | 39                | 21         | 54         | <0.001|
| TC, mg/dl                  | 188 (160 - 222)   | 192 (166 - 224) | 185 (159 - 217) | 0.358|
| LDL-c, mg/dl               | 111 (85 - 151)    | 116 (88 - 171) | 100 (84 - 137) | 0.660|
| HDL-c, mg/dl               | 44 (35 - 52)      | 44 (36 - 53) | 40 (31 - 49) | 0.160|
| TG, mg/dl                  | 96 (76 - 125)     | 90 (76 - 110) | 98 (77 - 128) | 0.310|
| Dyslipidemia, %            | 79                | 80         | 77         | 0.630 |
| MetS, %                    | 46                | 31         | 62         | <0.001|
| Creatinine, mg/dl          | 1.4 (1.0 - 2.6)   | 1.0 (0.9 - 1.2) | 2.8 (1.8 - 4.0) | <0.001|
| MDRD-GFR, ml/min/1.73m²    | 61 ± 37           | 89 ± 26    | 30 ± 15    | <0.001|
| Dipstick-proteinuria, %    | 17                | 6          | 28         | <0.001|
| RKF, stages, %             |                   |            |            |       |
| 3                          | -                 | -          | 46         |       |
| 4                          | -                 | -          | 36         |       |
| 5                          | -                 | -          | 18         |       |

Data are expressed as mean ± standard deviation, median (interquartile range) or relative frequency in percent. Abbreviations: RKF & NKF, reduced and relatively normal kidney function; Hb, hemoglobin; Ht, hematocrit; FPG, fasting plasma glucose; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; TG, triglycerides; MetS, metabolic syndrome; MDRD, modification of diet in renal disease; GFR, glomerular filtration rate.

Hypertensive patients (53% females, mean age 59 ± 12 years) with 46%, 36% and 18% being at RKF stage 3, 4 and 5, respectively. Compared to patients with normal renal function, those with RKF had in average a longer duration of hypertension [8 (4 - 12) vs. 6 (1 - 13) years; p = 0.040], higher BMI (27 ± 5 vs. 25 ± 4 Kg/m²; p = 0.047) and WC (95 ± 14 vs. 90 ± 13 cm; p = 0.031). Sixty-three percent, 27% and 5% of patients with RKF were receiving one, two and more than two antihypertensive drugs, respectively. Patients with RKF had also a significantly higher proportion (77% vs. 62%; p = 0.040) of subjects with uncontrolled hypertension compared to those with normal renal function. They had in addition significantly higher levels of FPG [101 (86 - 128) vs. 90 (79 - 97) mg/dl; p < 0.001], uric acid (7.4 ± 2.8 vs. 5.5 ± 2.2 mg/dl; p < 0.001) and lower hemoglobin levels (11 ± 2 vs. 13 ± 2 g/dl; p < 0.001).

Cardiovascular risk factors in the study population as a whole and according to renal function status are also depicted in Table 1 and Table 2. Patients with RKF had a higher proportion of subjects with global obesity (30 vs. 10%; p = 0.002), central obesity (55% vs. 39%; p = 0.048), diabetes (38% vs. 6%; p < 0.001), hyperuricemia (54% vs. 21%; p < 0.001), dipstick-proteinuria (28% vs. 6%; p <
0.001), MetS (62% vs. 31%; p < 0.001) and anemia (54% vs. 24%; p < 0.001).

The median echocardiographic-LVMI in non-obese and obese patients with RKF was 276 (198 - 348) g/m² and 72 (47 - 88) g/m², respectively (Figure 1 and Figure 2); these values were significantly higher than those observed in patients with normal renal function (p < 0.01, respectively). Echocardiographic-LVH was observed in 92% of patients with RKF with concentric and eccentric patterns in 50% and 42% of them, respectively. However, the differences observed in comparison with patients with normal renal function were not statistically significant.

**Figure 1.** Echocardiographic left ventricular mass index in non-obese patients according to kidney function status.

**Figure 2.** Echocardiographic left ventricular mass index in obese patients according to kidney function status.
Mean ECG-LVM in patients with RKF was 36 ± 11 mm, 21 ± 8 mm and 2087 ± 714 mm·sec for Sokolow-Lyon, Cornell voltage and Cornell product, respectively (Table 3). The prevalence of ECG-LVH in patients with RKF by voltage criteria was 45%, 22% and 23% for Sokolow-Lyon, Cornell voltage and Cornell product, respectively. However, the differences in prevalence of LVH between patients with and without RKF were not statistically significant.

The performance of the 3 ECG indexes for the diagnosis of LVH was similar in patients with than without RKF. Sensitivity and specificity were 43% and 85%, 23% and 77% and 26% and 77% for Sokolow-Lyon, Cornell voltage and Cornell product, respectively. However, the PPV of the 3 indexes were relatively high (>90%) (Table 4).

ROC curves of the 3 ECG indexes are presented in Figure 3. The performance of Sokolow-Lyon index for the diagnosis of LVH was low [area under the curve (AUC)]; 95% CI: 0.64; 0.50 - 0.78] while Cornell voltage (AUC: 0.42; 0.25 - 0.59) and Cornell product (AUC: 0.43; 0.28 - 0.59) showed no diagnostic interest. The optimal cut-point value of Sokolow-Lyon index corresponding to the highest Youden index was ≥37 mm (39.4% of sensitivity and 92.3% of specificity).

4. Discussion

The main findings of the present post-hoc analysis are as follows. First, the test performance of all the 3 ECG indexes was low. Second, Sokolow-Lyon index performed better than the two other indexes for the diagnosis of LVH.

The poor performance of ECG indexes in detecting LVH has been already reported in African Black hypertensives with and without RKF [4] [6] [30] [31] [32] [33] [34] as well as in the general population [7]. A similar finding has been also found in hypertensive patients out of Africa [35] [36] [37] [38] [39]. The reasons for the different performances of electrocardiographic criteria are not

Table 3. Electrocardiographic left ventricular mass and hypertrophy of the whole study population and according to kidney function status.

| ECG index               | All group n = 155 | NKF n = 81 | RKF n = 74 | P      |
|-------------------------|-------------------|------------|------------|--------|
| LVM                     |                   |            |            |        |
| Sokolow-Lyon, mm        | 34 ± 11           | 32 ± 11    | 36 ± 11    | 0.045  |
| Cornell Voltage, mm     | 21 ± 8            | 21 ± 8     | 21 ± 8     | 0.600  |
| Cornell Product, mm·sec | 2069 ± 722        | 2052 ± 734 | 2087 ± 714 | 0.761  |
| LVH                     |                   |            |            |        |
| Sokolow-Lyon, %         | 41                | 37         | 45         | 0.339  |
| Cornell-Voltage, %      | 23                | 25         | 22         | 0.651  |
| Cornell product, %      | 26                | 28         | 23         | 0.441  |
| 3 indexes combined, %   | 58                | 56         | 61         | 0.508  |

Data are expressed as mean ± standard deviation or relative frequency in percent. Abbreviations: RKF & NKF, reduced and relatively normal kidney function disease ECG, electrocardiogram LVM, left ventricular mass LVH, left ventricular hypertrophy.
Table 4. Performance of 3 ECG criteria of LVH versus echocardiography among the study population and according to kidney function status.

| ECG criteria          | All group n = 155 | NKF n = 81 | RKF n = 74 | P     |
|-----------------------|-------------------|------------|------------|-------|
| Sokolow-Lyon index    |                   |            |            |       |
| Se, %                 | 43                | 41         | 46         | 0.513 |
| Sp, %                 | 85                | 100        | 67         | -     |
| PPV, %                | 97                | 100        | 94         | -     |
| NPV, %                | 12                | 14         | 10         | 0.424 |
| Cornell voltage       |                   |            |            |       |
| Se, %                 | 23                | 24         | 22         | 0.785 |
| Sp, %                 | 77                | 71         | 83         | 0.111 |
| PPV, %                | 92                | 90         | 94         | 0.298 |
| NPV, %                | 8                 | 8          | 9          | 0.645 |
| Cornell product       |                   |            |            |       |
| Se, %                 | 26                | 28         | 24         | 0.566 |
| Sp, %                 | 77                | 71         | 83         | 0.111 |
| PPV, %                | 92                | 91         | 94         | 0.433 |
| NPV, %                | 9                 | 9          | 9          | 0.859 |
| 3 indexes combined    |                   |            |            |       |
| Se, %                 | 59                | 57         | 62         | 0.496 |
| Sp, %                 | 54                | 57         | 50         | 0.397 |
| PPV, %                | 93                | 93         | 93         | 0.875 |
| NPV, %                | 11                | 11         | 10         | 0.952 |

Abbreviations: RKF & NKF, reduced and normal kidney function disease ECG, electrocardiogram Se, sensitivity Sp, specificity PPV, positive predictive value NPV, negative predictive value.

Figure 3. ROC curve of Sokolow-Lyon index, Cornell voltage and Cornell product for diagnosis of left ventricular hypertrophy.
clear and understanding reasons for the discrepancies in detection of LVH by ECG versus imaging could help improve the diagnostic ability of ECG [40] [41]. These discrepancies are thought to rely upon a number of extracardiac factors such as age, gender, body habitus and cardiac factors such as LVH severity and geometry [7] [42]. With reference to cardiac factors, Bacharov et al. [40] [41] reported that differences in the prevalence estimates between ECG-based and imaging-based LVH could probably be explained by the complex structural and functional remodeling of the myocardium that occur as a result of hypertrophy. In addition to changes in the size of left ventricle, structural changes at the tissue level including changes of cardiomyocytes, interstitial fibrosis, diminished coronary reserve and myocardial dysfunction [40] [41] are common occurrences. These multi-dimension complex changes are not easily captured by a modality that depends on recording electric activity such as ECG. As a result of the complex structural and functional remodeling of myocardium occurring as a result of hypertrophy, the conduction velocity is slowed, and consequently the sequence of ventricular activation is altered [40] [41]. Using computer simulations, it has been shown that the mass and shape of the left ventricle in LVH are not the only determinant of QRS voltage, the key feature upon which almost all ECG-LVH criteria relies on [40] [41]. Diffuse or regional slowing in conduction velocity changes the sequence of ventricular activation in a way that is consistent with ECG-LVH patterns even in situations when the anatomy of left ventricle is not changed. These findings provide further support that the ECG criteria for LVH do not necessarily mirror changes in LV mass all the time, which explains the too many criteria, none of which provide a high level of diagnostic accuracy. Clearly, the usefulness of ECG-LVH as a tool for prediction of outcomes seems to surpass its value as a tool to diagnose anatomical LVH. Therefore, it may be the time to modify the current or create new ECG-LVH criteria with the main focus being prediction of outcomes rather than the anatomical correlates [40] [41].

In the present post-hoc analysis, Sokolow-Lyon index performed better than the two other comparator indexes. This finding contrasts with the generally accepted better performance of Cornell indexes vs. Sokolow-Lyon index reported by several studies [7] [35] [36] [43]. Noble et al. [44] tried to explain the better performance of Cornell-based criteria through vector cardiographic changes induced by LVH. Indeed, the LVM orients the electric forces horizontally corresponding to the RaVL and posteriorly corresponding to the SV3. Furthermore, the V3 lead is closer to the LV and is probably less influenced by variations in the distance between the myocardium and the leads. However, our finding is consistent with the report of a few studies [4] [32] [37] of a better performance of Sokolow-Lyon index vs. Cornell indexes. The exact mechanism underlying the better performance of Sokolow-Lyon index is not clear and could be related to age and BMI of the studied patients as well as the modality of LVM indexation. QRS voltage amplitude depends to both cardiac (electric properties of both the conduction system and the myocardium) and extra-cardiac factors such as age,
gender, BMI [40]. In this regard, Tsiachris et al. [45] reported that in elderly patients the Sokolow-Lyon index was associated with LVH detection when LVM was indexed for height whereas Cornell-based indexes were associated with echocardiographic detection of LVH indexed to BSA. In contrast to the above finding, Cornell voltage in middle-aged subjects was the only ECG index that was associated with LVH detection irrespective of indexation [46]. Another plausible explanation could be the fact that the evidence indicates that the sensitivity of several ECG criteria decreases from normal-weight to overweight and obesity [47]. In this regard, a recent study from Italy found that BMI-corrected Sokolow-Lyon voltage and Cornell voltage criteria provided better results for detection of echocardiographic LVH compared with unadjusted parameters [47]. LVH-induced conduction system abnormalities could also contribute to the observed better performance of Sokolow-Lyon index in the present post-hoc analysis. Indeed, Burgos et al. [48] reported in hypertensive patients that among ECG criteria with the best performance for LVH and complete Left bundle branch block (CLBBB), Sokolow-Lyon index stood out with a better sensitivity and specificity. They concluded that despite the significant decrease in performance with regards to sensitivity and specificity in patients with LVH and CLBBB, Sokolow-Lyon index presented the best performance.

The interpretation of the findings of the present analysis should consider some limitations. First, it was a post-hoc analysis with a small sample size; second, only a single observer made the diagnosis of echocardiographic LVH; it is well-known that echocardiographic measurements are observer dependent and no agreement test was carried out in the present analysis; third, the original study was a tertiary clinic-based cross-sectional study with selection bias; fourth, echocardiography was used for comparison instead of more accurate tools like computerized tomography or magnetic resonance imaging; unfortunately, these techniques were not available. However, echocardiography has been reported to have a strong correlation with autopsy findings [17]. Notwithstanding these limitations, the present study is the first one comparing the performance of ECG criteria in relation with echocardiography in our setting with limited resources.

5. Conclusion

Although the overall performance of ECG criteria studied was low, Sokolow-Lyon index had a better performance than that of the two others criteria in diagnosing LVH.

Acknowledgements

The authors gratefully thank the Head and all the staff of the Division of Cardiology of the Department of Internal Medicine of University of Kinshasa Hospital for their invaluable help in the conduct of the original study.

Author’s Contribution

L. F. B. wrote the protocol, participated in data analysis and wrote the manu-
script.

M. C. M. B. collected data, participated in data analysis and revised the manuscript.
M. F. I. N. conducted data analysis and revised the manuscript.
M. J. R. participated in data analysis and revised the manuscript.
K. P. K. participated in data analysis and revised manuscript.
K. F. M. revised the manuscript.
K. E. V. revised the manuscript.
M. K. J. R. revised the manuscript.

References

[1] Chahal, N.S., Lim, T.K., Jain, P., et al. (2010) New Insights into the Relationship of Left Ventricular Geometry and Left Ventricular Mass with Cardiac Function: A Population Study of Hypertensive Subjects. European Heart Journal, 31, 588-594. https://doi.org/10.1093/eurheartj/ehp490

[2] Schiffrin, E., Lipman, M.L. and Mann, J.F.E. (2007) Chronic Kidney Disease. Effects on Cardiovascular System. Circulation, 116, 85-97. https://doi.org/10.1161/CIRCULATIONAHA.106.678342

[3] Pewsner, D., Juni, P., Egger, M., et al. (2007) Accuracy of Electrocardiography in the Diagnosis of Left Ventricular Hypertrophy in Arterial Hypertension: A Systematic Review. BMJ, 335, 711. https://doi.org/10.1136/bmj.39276.636354.AE

[4] Ogunlanle, O. and Akintomide, A.O. (2013) Assessment of Voltage Criteria for Left Ventricular Hypertrophy in Adult Hypertensives in Southern-Western Nigeria. Journal of Cardiovascular Disease Research, 4, 44-46.

[5] Costa, F.A., Rivera, I.R., Castro de Vasconcelos, M.L., et al. (2009) Electrocardiography in the Diagnosis of Left Ventricular Hypertrophy in Patients with Chronic Renal Disease. Arquivos Brasileiros de Cardiologia, 93, 353-359.

[6] Busari, O., Opadijo, G., Olarewaju, T., Omotoso, A. and Jimoh, A. (2010) Electrocardiographic Correlates of Microalbuminuria in Adult Nigerians with Essential Hypertension. Cardiology Journal, 17, 281-287.

[7] Jingi, A.M., Noubiap, J.J.N., Kamdem, P. and Kingue, S. (2014) Determinants and Improvement of Electrocardiographic Diagnosis of Left Ventricular Hypertrophy in a Black African Population. PLoS ONE, 9, e9883. https://doi.org/10.1371/journal.pone.0098678

[8] Devereux, R.B. (1990) Is the Electrocardiogram Still Useful for the Detection of Left Ventricular Hypertrophy? Circulation, 81, 144. https://doi.org/10.1161/01.CIR.81.3.1144

[9] Lorell, B.H. and Carabello, B.A. (2000) Left Ventricular Hypertrophy: Pathogenesis, Detection, and Prognosis. Circulation, 102, 470. https://doi.org/10.1161/01.CIR.102.4.470

[10] Courand, Y., Lantelme, P. and Gosse, P. (2015) Electrocardiographic Detection of Left Ventricular Hypertrophy: To Forget the Sokolow-Lyon Index? Archives of Cardiovascular Diseases, 108, 277-280. https://doi.org/10.1016/j.acvd.2015.03.003

[11] M’Buyamba-Kabangu, J.R., Fagard, R., Staessen, J., Lijnen, P. and Amery, A. (1987) Comparison of Blood Pressure and Prevalence of Hypertension in Rural and Urban Zaire. Bibliotheca Cardiologica, 42, 80-87.

[12] Sumaili, E.K., Nseka, M.N., Lepira, F.B., et al. (2008) Screening for Proteinuria and Chronic Kidney Disease Risk Factors in Kinshasa: A World Kidney Day 2007 Study.
[13] Katchunga, P.B., M’Buyamba-Kabangu, J.R., Masumbuko, B.E., et al. (2011) Hypertension in the Adult Congolese Population of Southern Kivu: Results of VITARAA Study. La Presse Médicale, 40, e315623. (In French)

[14] M’Buyamba-Kabangu, J.R., Biswika, R.T., Thijs, L., et al. (2009) In-Hospital Mortality among Black Patients Admitted for Hypertension-Related Disorders in Mbuji Mayi, Democratic Republic of the Congo. American Journal of Hypertension, 22, 643-648. https://doi.org/10.1038/ajh.2009.47

[15] Lepira, F.B., M’Buyamba-Kabangu, J.R., Kayembe, P.K. and Nseka, M.N. (2006) Clinical Correlates of Left Ventricular Hypertrophy in Black Patients with Arterial Hypertension. Cardiovascular Journal of Africa, 17, 7-11.

[16] Mpembe, B.C., Lepira, F.B., Mbutiwi, F.I., et al. (2015) Left Ventricular Structure, Geometry and Systolic Function among Hypertensive Black Patients with Chronic Kidney Disease. World Journal of Cardiovascular Diseases, 5, 287-295. http://www.scirp.org/journal/wjcd

[17] Devereux, R.B., Alonso, D.R., Lucas, E.M., et al. (1986) Echocardiographic Assessment of Left Ventricular Hypertrophy: Comparison to Necropsy Findings. American Journal of Cardiology, 57, 450-458. https://doi.org/10.1016/0002-9149(86)90771-X

[18] de Simone, G., Kizer, J.R. and Devereux, R.B. (2005) Normalization for Body Size and Population Attributable Risk of Left Ventricular Hypertrophy: The Strong Heart Study. American Journal of Hypertension, 18, 191-196. https://doi.org/10.1016/j.amjhyper.2004.08.032

[19] World Health Organization (WHO) (2000) The Problem of Overweight and Obesity: Preventing and Managing the Global Epidemic. Report Series 894, Geneva, 537.

[20] Dimitrieva, O., de Lusignan, S. and Goldsmith, D. (2013) Association of Anemia in Primary Care Patients with Chronic Kidney Disease. Cross-Sectional Study of Quality Improvement in Chronic Kidney Disease (AICKD) Trial Data. BMC Nephrology, 14, 24. https://doi.org/10.1186/1471-2369-14-24

[21] National Heart, Lung and Blood Institute (2001) Executive Summary of the National Cholesterol Education Program (NCEP) Expert Panel on Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA, 285, 2486-2497. https://doi.org/10.1001/jama.285.19.2486

[22] Mansia, G., De Backer, G., Dominiczak, A., et al. (2007) Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): The Task Force for the Management of Arterial Hypertension of ESH and ESC. Blood Pressure, 16, 135-232. https://doi.org/10.1080/08037050701461084

[23] De Simone, G., Devereux, R.B., Daniels, S.R., et al. (1995) Effect of Growth Variability on Left Ventricular Hypertrophy: Assessment of Alternative Signals in Adults and Children and Their Capacity to Predict Cardiovascular Risk. Journal of the American College of Cardiology, 25, 1056-1061.

[24] De Simone, G., Daniels, S.R., Devereux, R.B., et al. (1992) Left Ventricular Mass and Body Size in Normotensive Children and Adults: Assessment of Allometric Relations and Impact of Overweight. Journal of the American College of Cardiology, 20, 1251-1260.

[25] Sokolow, M. and Lyon, T.P. (1949) The Ventricular Complex in Left Ventricular Hypertrophy as Obtained by Unipolar Precordial and Limb Leads. American Heart Journal, 37, 161-186. https://doi.org/10.1016/0002-8703(49)90562-1
[26] Casale, P.N., Devereux, R.B., Kligfield, P., et al. (1985) Electrocardiographic Detection of Left Ventricular Hypertrophy Development and Prospective Validation of Improved Criteria. *Journal of the American College of Cardiology*, 6, 572-580.

[27] Norman Jr., J.E. and Levy, D. (1996) Adjustment of ECG Left Ventricular Hypertrophy Criteria for Body Mass Index and Age Improves Classification Accuracy: The Effects of Hypertension and Obesity. *Journal of Electrocardiology*, 29, 241-247. [https://doi.org/10.1016/S0022-0736(96)80070-7](https://doi.org/10.1016/S0022-0736(96)80070-7)

[28] National Kidney Foundation. K/DOQI. Clinical Practical Guidelines for Chronic Kidney Disease (CKD) (2002) Evaluation, Classification and Stratification. Kidney Disease Outcome Quality Initiative. *American Journal of Kidney Diseases*, 39, S1-S266.

[29] Delacour, A.L., Servonnet, A., Perrot, A., Vigezzi, J.F. and Ramirez, J.M. (2005) Receiver Operating Characteristic (ROC) Curves: Principles and Main Applications in Clinical Biology. *Annales de Biologie Clinique*, 63, 145-154. (In French)

[30] Dzudie, A., Muna, W., Kingue, S., et al. (2009) Electrocardiograms to Assess Left Ventricular Hypertrophy in Black African Hypertensives. 1st Panafrican Congress on Hypertension Organized by International Forum for Hypertension Prevention and Control in Africa (IPFA), Abstract 005.

[31] Adebiyi, A.A., Ogah, O.S., Aje, A., et al. (2006) Echocardiographic Partition Values and Prevalence of Left Ventricular Hypertrophy in Hypertensive Nigerians. *BMC Medical Imaging*, 6, 10. [https://doi.org/10.1186/1471-2342-6-10](https://doi.org/10.1186/1471-2342-6-10)

[32] Dada, A., Adebiyi, A.A., Aje, A., Oladipo, O.O. and Falase, A.O. (2006) Comparison of Araoye’s Criteria with Standard Electrocardiographic Criteria for Left Ventricular Hypertrophy in Nigerian Hypertensives. *West African Journal of Medicine*, 25, 179-185.

[33] Dada, A., Adebiyi, A.A., Aje, A., Oladipo, O.O. and Falase, A.O. (2005) Standard Electrocardiographic Criteria for Left Ventricular Hypertrophy in Nigerian Hypertensives. *Ethnicity & Disease*, 15, 578-584.

[34] Katibi, J.A. (1996) Left Ventricular Hypertrophy among Hypertensive Nigerians: Correlation between Echocardiogram and Electrocardiogram. WACP Dissertation, West African Postgraduate Medical College, Lagos.

[35] Cordeiro, A.C., Lindholm, B., Sousa, M.G., et al. (2014) Reliability of Electrocardiographic Surrogates of Left Ventricular Mass in Patients with Chronic Kidney Disease. *Journal of Hypertension*, 32, 439-445.

[36] Rodriguez, S.L., D’Angelo, L., Pereira, C., Krieger, J.E. and Mill, J.G. (2008) Revision of the Sokolow-Lyon-Rappaport and Cornell Voltage Criteria for Left Ventricular Hypertrophy. *Arquivos Brasileiros de Cardiologia*, 90, 44-51.

[37] Verdecchia, P., Devellini, E.V., Gorini, M., et al. (2000) Comparison of Electrocardiographic Criteria for Diagnosis of Left Ventricular Hypertrophy in Hypertension: The MAVI Study. *Italian Heart Journal*, 1, 207-213.

[38] Schillaci, G., Verdecchia, P., Borgioni, C., et al. (1994) Improved Electrocardiographic Diagnosis of Left Ventricular Hypertrophy. *American Journal of Cardiology*, 74, 714-719. [https://doi.org/10.1016/0002-9149(94)90316-6](https://doi.org/10.1016/0002-9149(94)90316-6)

[39] Levy, D., Bailey, J.J., Garrison, R.J., et al. (1987) Electrocardiographic Changes with Advancing Age. A Cross-Sectional Study of the Association of Age with QRS Axis, Duration and Voltage. *Journal of Electrocardiology*, 20, 44-47.

[40] Bacharova, L., Schocken, D., Estes, E.H. and Strauss, D. (2014) The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy. *Current Cardiology Review*, 10, 257-261. [https://doi.org/10.2174/1573403X10666140514103220](https://doi.org/10.2174/1573403X10666140514103220)
[41] Bacharova, L., Chen, H., Estes, E.H., Mateasik, A., Bluemke, D.A., Lima, J.A.C., et al. (2015) Determinants of Discrepancies in Detection and Comparison of the Prognostic Significance of Left Ventricular Hypertrophy by Electrocardiogram and Cardiac Magnetic Resonance Imaging. The American Journal of Cardiology, 115, 515-522. https://doi.org/10.1016/j.amjcard.2014.11.037

[42] Maunganidze, F., Woodiwiss, A.J., Libhader, C.D., et al. (2013) Obesity Markedly Attenuates the Validity and Performance of All Electrocardiographic Criteria for Left Ventricular Hypertrophy Detection in a Group of Black African Ancestry. Journal of Hypertension, 31, 377-383. https://doi.org/10.1097/HJH.0b013e32835b8daa

[43] Park, J.K., Shin, J.H., Kim, S.H., et al. (2012) A Comparison of Cornell and Sokolow-Lyon Electrocardiographic Criteria for Left Ventricular Hypertrophy in Korean patients. Korean Circulation Journal, 42, 606-613. https://doi.org/10.4070/kcj.2012.42.9.606

[44] Noble, L.M., Humphrey, S.B. and Monoghan, G.B. (1984) Left Ventricular Hypertrophy in Left Bundle Branch Block. Journal of Electrocardiology, 17, 157-160. https://doi.org/10.1016/S0022-0736(84)81090-0

[45] Tsiachris, D., Chrysogou, C., Oikonomou, E., et al. (2011) Distinct Role of Electrocardiographic Criteria in Echocardiographic Diagnosis of Left Ventricular Hypertrophy According to Age in the General Population: The IKARA Study. Journal of Hypertension, 29, 1624-1632. https://doi.org/10.1097/HJH.0b013e3283487780

[46] Calderon, A., Barrios, V., Escobar, C., et al. (2010) Detection of Left Ventricular Hypertrophy by Different Electrocardiographic Criteria in Clinical Practice: Findings from the Sara Study. Clinical and Experimental Hypertension, 32, 145-153. https://doi.org/10.3109/10641960903254455

[47] Cuspidi, C., Facchetti, R., Bombelli, M., et al. (2016) Does QRS Correction by Body Mass Index Improve the Accuracy of Electrocardiography in Detecting Left Ventricular Hypertrophy and Predicting Cardiovascular Events in a General Population? The Journal of Clinical Hypertension (Greenwich), 18, 415-421. https://doi.org/10.1111/jch.12678

[48] Burgos, P.F., Filho, L., Costa, F.A., et al. (2017) Electrocardiogram Performance in the Diagnosis of Left Ventricular Hypertrophy in Hypertensive Patients with Left Bundle Branch Block. Arquivos Brasileiros de Cardiologia, 108, 47-52.